查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011317

動物生物技術市場：依產品類型、技術、應用和最終用戶分類－2026-2032年全球預測

Animal Biotechnology Market by Product Type, Technology, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，動物生物技術市場價值將達到 338.1 億美元，到 2026 年將成長至 364.9 億美元，到 2032 年將達到 605.6 億美元，複合年成長率為 8.68%。

主要市場統計數據
基準年 2025 338.1億美元
預計年份：2026年 364.9億美元
預測年份 2032 605.6億美元
複合年成長率 (%) 8.68%

動物生物技術策略方法，將科學創新、監管發展和供應鏈韌性作為商業決策的核心驅動力。

動物生物技術正處於一個轉折點，分子工具、生產平台和法規結構的進步相互交融，重新定義了動物健康、營養和研究解決方案的開發和應用方式。該產業如今涵蓋重組蛋白、疫苗創新、精準飼料添加劑和診斷技術，不僅支持畜牧業生產力，也支持生物醫學研究和轉化科學。投資者、政策制定者和商業領袖越來越關注那些能夠改善動物福利、建立具有韌性的價值鏈、加速研發週期並減少環境影響的技術。

技術變革、不斷演變的商業化模式以及監管調整正在重塑動物生物技術領域的競爭動態。

動物生物技術領域正經歷一場變革，其驅動力來自於平台技術的成熟和商業化路徑的演進。基因編輯工具和基因改造調查方法正從概念驗證（PoC）階段邁向應用案例階段，加速表現型工程​​和疫苗抗原設計。同時，包括禽類、昆蟲和哺乳動物平台在內的細胞培養系統的改進，使得生物製藥生產更具規模化和成本效益，並減少了對傳統製程的依賴。定序和診斷技術的進步也為這些技術變革提供了補充，次世代定序和改進的PCR工作流程提高了分析解析度並加快了結果出爐速度。

了解 2025 年關稅變化將如何重塑整個動物生物技術價值鏈的供應鏈、籌資策略和營運風險框架。

2025年美國關稅政策的發展正對動物生物技術領域的供應鏈經濟、籌資策略和產業計畫產生累積影響。試劑、實驗室設備和特殊組件進口關稅的提高推高了進口後的投入成本，擠壓了製造商和服務供應商的利潤空間。為應對這項挑戰，企業正在加速供應商多元化，與美國以外的供應商簽訂長期契約，並探索近岸外包和回流生產等方案，以降低關稅波動帶來的風險。這些變化正在對採購週期、庫存管理和資本配置決策產生後續影響。

詳細的細分分析揭示了產品、技術、應用和最終用戶方面的差異如何決定開發重點、市場模式和投資重點。

細分趨勢揭示了每種產品類型、技術、應用和最終用戶實現價值創造和業務優先事項的清晰路徑。按產品類型分類，該領域涵蓋重組蛋白和疫苗。重組蛋白包括抗體、酵素和生長激素，其中酵素的亞類包括脂肪酶、植酸酶和蛋白酶。另一方面，疫苗包括DNA疫苗、去活化疫苗、減毒活病毒疫苗和次單位疫苗。這種多樣性要求採用差異化的開發策略。對於抗體而言，特異性和大規模生產是優先考慮的因素；對於酵素而言，熱穩定性和與飼料的整合至關重要；而對於每種疫苗類型，都需要適當的低溫運輸和監管措施。

區域比較分析表明，美洲、歐洲、中東、非洲和亞太地區的趨勢如何影響監管策略、製造和採用軌跡。

區域趨勢影響著美洲、歐洲、中東和非洲以及亞太地區的機會範圍、法律規範和應用軌跡。在美洲，完善的研究基礎設施和大量的私人投資正在加速新型生物製藥和診斷平台的快速應用，而物流中心和先進製造群則為合約開發和生產（CDMO）活動提供了支援。北美與監管機構的對話日益側重於監管協調和創新治療方法的快速核准流程，從而創造出積極主動的監管策略管理環境，進而實現更可預測的規模化和商業化。

如何透過垂直整合、平台差異化和人才優先等企業策略來決定動物生物技術領域的競爭地位。

動物生物技術領域的企業策略正趨於形成幾種可重複的模式，這些模式預示著整體競爭格局中的贏家和輸家。主要企業正尋求垂直整合和策略夥伴關係，以確保關鍵投入、縮短產品上市時間並拓展增值服務。合約研發生產機構（CDMO）正投資於平台柔軟性，以適應重組蛋白和疫苗的生產模式，從而獲得更廣泛的外包研發和生產市場佔有率。同時，專業技術供應商正透過專有細胞株、最佳化的發酵製程或獨特的定序和診斷化學技術來實現差異化，從而為特定終端用戶提供性能優勢。

為領導者提供切實可行的策略，以加強供應鏈、模組化製造、積極與監管機構互動，並加速基於平台的創新，以實現商業性擴充性。

行業領導者應採取一系列切實措施，將科學知識轉化為永續的商業性優勢。首先，透過認證多家地理位置分散的供應商、確保關鍵試劑的策略性庫存緩衝以及投資供應鏈視覺化系統來分散採購和物流，從而預防中斷。其次，優先投資模組化生產，以實現重組蛋白和疫苗生產之間的快速轉換，縮短切換時間並最大限度地提高產能運轉率。第三，積極與監管機構溝通，參與相關工作小組，儘早提交試點資料包，並設計符合不斷變化的監管要求的臨床和安全方案。

結合專家訪談、文獻整合、專利和監管檢驗以及資料三角驗證的多方面研究框架，確保了穩健且可操作的見解。

本分析基於多方法研究，整合了專家訪談、二手文獻以及結構化資料的三角驗證。主要資料來源包括對學術界、產業界和合約服務供應商(CSP) 的高級研發負責人、製造企業高管和監管專家的保密檢驗，這些訪談構成了情境建構的基礎，並有助於檢驗新興趨勢。二手研究涵蓋了同行評審文獻、專利申請、監管指導文件和技術白皮書，旨在建立技術採納和製造演進的科學和監管背景。

這份高層結論總結了綜合科學創新、監管靈活性和營運韌性如何決定動物生物技術領域的長期成功。

總之，動物生物技術的發展離不開科學創新、供應鏈重組和監管調整的相互作用，這三者共同為市場參與企業創造了機會和挑戰。細胞培養、基因工程和定序技術的進步帶來了新的產品類型和效率提升，而關稅趨勢和區域政策變化則迫使企業重新評估其採購、生產和夥伴關係策略。能夠將平台能力轉化為可重複的生產流程、保持監管適應性並建立能夠降低地緣政治和物流風險的彈性供應鏈網路的企業，才能最終取得成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：動物生物技術市場：依產品類型分類

  • 重組蛋白
    • 抗體
    • 酵素
      • 脂肪酶
      • 植酸酶
      • 蛋白酶
    • 生長激素
  • 疫苗
    • DNA疫苗
    • 去活化疫苗
    • 減毒活病毒疫苗
    • 次單位疫苗

第9章：動物生物技術市場：依技術分類

  • 細胞培養
    • 禽類細胞培養
    • 昆蟲細胞培養
    • 哺乳動物細胞培養
  • 基因工程
    • 基因編輯
    • 基因合成
    • 基因改造技術
  • PCR和DNA定序
    • 次世代定序
    • PCR試劑盒
    • 桑格定序

第10章 動物生物技術市場：依應用領域分類

  • 診斷
    • ELISA試劑盒
    • 橫向流動化驗
    • 基於PCR的檢測
  • 藥物發現
    • 先導藥物最適化
    • 臨床前試驗
    • 目標識別
  • 飼料添加劑
    • 碳水化合物消化酶
    • 植酸酶
    • 蛋白酶

第11章 動物生物技術市場：依最終用戶分類

  • 畜牧場
  • 合約研究機構
  • 製藥公司
  • 研究機構

第12章 動物生物技術市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：動物生物技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 動物生物技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國動物生物技術市場

第16章：中國動物生物技術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Animal Genetics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals plc
  • Elanco Animal Health Incorporated
  • Genus plc
  • Hendrix Genetics BV
  • HIPRA SA
  • IDEXX Laboratories, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Phibro Animal Health Corporation
  • Recombinetics, Inc.
  • Thermo Fisher Scientific Inc.
  • Trans Ova Genetics, LC
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-437517DB6EAD

The Animal Biotechnology Market was valued at USD 33.81 billion in 2025 and is projected to grow to USD 36.49 billion in 2026, with a CAGR of 8.68%, reaching USD 60.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 33.81 billion
Estimated Year [2026] USD 36.49 billion
Forecast Year [2032] USD 60.56 billion
CAGR (%) 8.68%

A strategic orientation to animal biotechnology that frames scientific innovation, regulatory evolution, and supply chain resilience as core drivers of executive decision making

Animal biotechnology stands at an inflection point where advances in molecular tools, manufacturing platforms, and regulatory frameworks converge to redefine how animal health, nutrition, and research solutions are developed and deployed. The industry now spans recombinant proteins, vaccine innovation, precision feed additives, and diagnostics that support not only livestock productivity but also biomedical research and translational science. Investors, policy makers, and corporate leaders are increasingly focused on resilient value chains, accelerated development timelines, and technologies that reduce environmental footprint while enhancing animal welfare.

Emergent capabilities in gene editing, high-throughput sequencing, and advanced cell culture are enabling new classes of biologics and platform technologies whose downstream effects will extend across therapeutic development, diagnostic throughput, and farm-level adoption. At the same time, intensifying public scrutiny, evolving trade policies, and shifting procurement practices are prompting organizations to reassess sourcing strategies and regulatory readiness. This introduction frames the critical levers-technology, policy, supply chain, and commercial strategy-that executives must prioritize to convert scientific opportunity into sustainable competitive advantage across the animal biotechnology ecosystem.

How technological inflection points, evolving commercialization models, and regulatory adaptation are reshaping competitive dynamics in animal biotechnology

The landscape of animal biotechnology is undergoing transformative shifts driven by the maturation of platform technologies and evolving commercialization pathways. Gene editing tools and transgenic methodologies have moved from proof-of-concept stages to operational use cases that accelerate trait engineering and vaccine antigen design. Concurrently, improvements in cell culture systems-including avian, insect, and mammalian platforms-are enabling more scalable and cost-efficient biologics manufacturing that reduces dependence on legacy processes. These technological inflections are also complemented by advances in sequencing and diagnostics, where next-generation sequencing and improved PCR workflows are increasing analytic resolution and shortening time-to-result horizons.

Commercial models are also shifting: contract development and manufacturing organizations are expanding capabilities to offer end-to-end services, while partnerships between research laboratories and industry actors are becoming the norm to share risk and speed deployment. Regulatory authorities are adapting to new modalities with more iterative, science-based dialogues, while sustainability pressures are pushing firms to seek lower-emissions manufacturing footprints and alternative inputs. Together, these shifts are altering competitive dynamics and creating new pathways for organizations that can integrate platform technologies, agile regulatory strategies, and resilient supply models to capture emerging opportunities in animal biotechnology.

Understanding how 2025 tariff shifts are recalibrating supply chains, sourcing strategies, and operational risk frameworks across the animal biotechnology value chain

Tariff policy developments in the United States in 2025 are exerting cumulative effects on supply chain economics, sourcing strategies, and operational planning within the animal biotechnology sector. Increased import duties on reagents, laboratory equipment, and specialized components raise landed input costs and compress margins for manufacturers and service providers. Companies are responding by accelerating supplier diversification, securing longer-term contracts with non-U.S. vendors, and exploring near-shoring or reshoring options to mitigate exposure to tariff volatility. These changes have downstream implications for procurement cycles, inventory management, and capital allocation decisions.

Beyond immediate cost pressures, tariff-driven realignments influence strategic partnerships and R&D collaborations. Organizations that previously relied on cross-border exchanges for early-stage research materials may pivot toward domestic suppliers or broaden collaborative networks to include geographically diversified research partners. Regulatory compliance and customs processes have become more complex, increasing administrative overhead for cross-border shipments of biologics and diagnostic kits. As a result, firms are investing in supply chain visibility tools and dual-sourcing strategies to maintain continuity. In parallel, the tariff environment is prompting some stakeholders to accelerate investments in local manufacturing capacity, which can reduce tariff exposure but requires careful consideration of workforce availability, capital intensity, and regulatory approvals. Overall, the tariff landscape is driving a recalibration of risk frameworks and operational models that will influence strategic planning for the foreseeable future.

Detailed segmentation analysis revealing how product, technology, application, and end-user distinctions determine development priorities, go-to-market models, and investment focus

Segmentation dynamics reveal distinct pathways to value and operational priorities across product types, technologies, applications, and end users. Based on product type, the sector spans recombinant proteins and vaccines; recombinant proteins include antibodies, enzymes, and growth hormones, and the enzymes subset comprises lipases, phytases, and proteases, while vaccines encompass DNA vaccines, inactivated vaccines, live attenuated vaccines, and subunit vaccines. This diversity requires differentiated development strategies: antibodies prioritize specificity and manufacturing scale, enzymes emphasize thermostability and feed integration, and vaccine modalities demand tailored cold-chain and regulatory approaches.

Based on technology, the market includes cell culture, genetic engineering, and PCR and DNA sequencing; cell culture further breaks down into avian, insect, and mammalian cell culture, genetic engineering covers gene editing, gene synthesis, and transgenic technology, while PCR and DNA sequencing span next-generation sequencing, PCR kits, and Sanger sequencing. These technological axes shape capital intensity, talent requirements, and regulatory interfaces. Based on application, the landscape includes diagnostics, drug discovery, and feed additives; diagnostics subdivide into ELISA kits, lateral flow assays, and PCR-based tests, drug discovery covers lead optimization, preclinical testing, and target identification, and feed additives include carbohydrases, phytases, and proteases. Application-driven segmentation highlights where value accrues: diagnostics deliver recurrent consumable demand, drug discovery requires extended R&D investment, and feed additives emphasize agricultural integration. Based on end-user, demand is sourced from animal farms, contract research organizations, pharmaceutical companies, and research laboratories. Each end-user presents unique procurement patterns and service-level expectations, requiring vendors to align product design, regulatory support, and commercial models to end-user priorities and operational constraints.

Comparative regional intelligence demonstrating how Americas, Europe Middle East and Africa, and Asia-Pacific dynamics influence regulatory strategy, manufacturing, and adoption trajectories

Regional dynamics shape opportunity sets, regulatory contours, and adoption trajectories across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established research infrastructure and significant private investment foster rapid adoption of novel biologics and diagnostic platforms, while logistical hubs and advanced manufacturing clusters support contract development and manufacturing activity. North American regulatory dialogues increasingly emphasize harmonization and expedited pathways for innovative modalities, creating an environment where scale-up and commercial launch can proceed with greater predictability when regulatory strategies are proactively managed.

In Europe, the Middle East and Africa, regulatory diversity and complex cross-border trade arrangements require granular regulatory intelligence and adaptable supply chains. The region combines mature scientific centers with markets that are still developing capacity for advanced biologics, making partnerships and public-private initiatives particularly valuable. Policy priorities around animal welfare and sustainability often shape procurement preferences in this region. In the Asia-Pacific, a combination of rapid market growth, expanding domestic manufacturing capability, and increasing public research funding is accelerating adoption of vaccines, feed additives, and diagnostics. Local manufacturers and research institutions are scaling capabilities in cell culture and genetic engineering, and cross-border collaborations are common as firms leverage cost-competitive production while accessing large regional demand pools. Across all regions, firms that craft localized regulatory strategies and supply chain architectures will gain an edge in commercial execution.

How corporate strategies combining vertical integration, platform differentiation, and talent prioritization are determining competitive positioning in animal biotechnology

Company strategies in animal biotechnology are converging on several repeatable patterns that signal winners and pressure points across the competitive landscape. Leading actors are pursuing vertical integration and strategic partnerships to secure critical inputs, reduce time-to-market, and expand value-added service offerings. Contract development and manufacturing organizations are investing in platform flexibility to accommodate both recombinant proteins and vaccine modalities, enabling them to capture a broader share of outsourced development and production demand. At the same time, specialist technology providers are differentiating through proprietary cell lines, optimized fermentation processes, or unique sequencing and diagnostic chemistries that deliver performance advantages for specific end-users.

Investment profiles show a balance between R&D intensity for next-generation modalities and operational investments in scale, quality systems, and regulatory affairs. Talent acquisition and retention have emerged as key competitive factors, with companies prioritizing cross-disciplinary teams that combine molecular biology expertise with regulatory, manufacturing, and commercialization experience. Strategic M&A and licensing transactions are being used to access niche technologies or expand geographic reach, while alliances between academic institutions and commercial developers accelerate translational milestones. Overall, organizations that combine platform innovation with robust regulatory roadmaps and flexible manufacturing partnerships are best positioned to capture emerging opportunities across animal health, feed solutions, and diagnostic applications.

Actionable strategies for leaders to fortify supply chains, modularize manufacturing, engage regulators proactively, and accelerate platform-based innovation for commercial scalability

Industry leaders should adopt a suite of tangible actions to convert scientific capability into durable commercial advantage. First, diversify procurement and logistics by qualifying multiple suppliers across geographies, establishing strategic inventory buffers for critical reagents, and investing in supply chain visibility systems to anticipate disruptions. Second, prioritize modular manufacturing investments that allow rapid reconfiguration between recombinant proteins and vaccine production, reducing changeover time and maximizing capacity utilization. Third, commit to proactive regulatory engagement by participating in jurisdictional working groups, submitting pilot data packages early, and designing clinical and safety programs that align with evolving agency expectations.

Fourth, accelerate platform-based innovation by standardizing analytical methods, sharing validated cell lines or assay formats where permissible, and pursuing partnerships that co-fund translational milestones. Fifth, enhance commercial adoption through end-user education programs that demonstrate product efficacy, ease of use, and return on operational metrics for animal farms and research laboratories. Sixth, manage talent risk through targeted recruitment, professional development, and cross-functional governance that ensures continuity across R&D, manufacturing, and regulatory teams. Implementing these recommendations will enable organizations to mitigate near-term policy headwinds, optimize capital deployment, and build scalable operations aligned with long-term scientific and commercial objectives.

A multi-method research framework combining expert interviews, literature synthesis, patent and regulatory review, and data triangulation to ensure robust and actionable insights

This analysis is based on a multi-method research approach that integrates primary expert engagement, secondary literature synthesis, and structured data triangulation. Primary inputs included confidential interviews with senior R&D leaders, manufacturing executives, and regulatory specialists across academia, industry, and contract service providers; these interviews informed scenario development and validated emergent trends. Secondary research encompassed peer-reviewed literature, patent filings, regulatory guidance documents, and technical white papers to establish the scientific and regulatory context for technology adoption and manufacturing evolution.

Quantitative and qualitative findings were cross-checked through triangulation to reconcile divergent perspectives and to highlight consensus areas. The research process also included value-chain mapping exercises to identify critical bottlenecks in sourcing, production, and distribution, and a review of public procurement and policy developments to assess potential commercial implications. Quality assurance measures included independent peer review by domain experts, source transparency protocols, and iterative feedback loops with subject-matter specialists to ensure robustness and relevance of conclusions.

Executive conclusion summarizing how integrated scientific innovation, regulatory agility, and operational resilience will determine long-term success within animal biotechnology

In conclusion, animal biotechnology is evolving through an interplay of scientific innovation, supply chain realignment, and regulatory adaptation that together create both opportunity and complexity for market participants. Technological advances in cell culture, genetic engineering, and sequencing are unlocking new product classes and efficiencies, while tariff dynamics and regional policy shifts are forcing organizations to reassess sourcing, manufacturing, and partnership strategies. Successful players will be those that translate platform capabilities into reproducible manufacturing processes, maintain regulatory agility, and construct resilient supply networks that mitigate geopolitical and logistical risks.

Looking ahead, the ability to synthesize scientific rigor with operational excellence will determine which organizations capture sustained value. Firms that invest in modular manufacturing, cultivate diversified supplier ecosystems, and engage proactively with regulators will be better positioned to convert R&D breakthroughs into scalable products and services. The path forward requires a balance of innovation, disciplined execution, and strategic partnerships that together will drive long-term growth and impact across animal health, nutrition, and research domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Biotechnology Market, by Product Type

  • 8.1. Recombinant Proteins
    • 8.1.1. Antibodies
    • 8.1.2. Enzymes
      • 8.1.2.1. Lipases
      • 8.1.2.2. Phytases
      • 8.1.2.3. Proteases
    • 8.1.3. Growth Hormones
  • 8.2. Vaccines
    • 8.2.1. DNA Vaccines
    • 8.2.2. Inactivated Vaccines
    • 8.2.3. Live Attenuated Vaccines
    • 8.2.4. Subunit Vaccines

9. Animal Biotechnology Market, by Technology

  • 9.1. Cell Culture
    • 9.1.1. Avian Cell Culture
    • 9.1.2. Insect Cell Culture
    • 9.1.3. Mammalian Cell Culture
  • 9.2. Genetic Engineering
    • 9.2.1. Gene Editing
    • 9.2.2. Gene Synthesis
    • 9.2.3. Transgenic Technology
  • 9.3. PCR And DNA Sequencing
    • 9.3.1. Next-Generation Sequencing
    • 9.3.2. PCR Kits
    • 9.3.3. Sanger Sequencing

10. Animal Biotechnology Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. ELISA Kits
    • 10.1.2. Lateral Flow Assays
    • 10.1.3. PCR-Based Tests
  • 10.2. Drug Discovery
    • 10.2.1. Lead Optimization
    • 10.2.2. Preclinical Testing
    • 10.2.3. Target Identification
  • 10.3. Feed Additives
    • 10.3.1. Carbohydrases
    • 10.3.2. Phytases
    • 10.3.3. Proteases

11. Animal Biotechnology Market, by End-User

  • 11.1. Animal Farms
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Laboratories

12. Animal Biotechnology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Biotechnology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Biotechnology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Animal Biotechnology Market

16. China Animal Biotechnology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Animal Genetics, Inc.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Biogenesis Bago S.A.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Ceva Sante Animale S.A.
  • 17.10. Dechra Pharmaceuticals plc
  • 17.11. Elanco Animal Health Incorporated
  • 17.12. Genus plc
  • 17.13. Hendrix Genetics BV
  • 17.14. HIPRA S.A.
  • 17.15. IDEXX Laboratories, Inc.
  • 17.16. Merck & Co., Inc.
  • 17.17. Neogen Corporation
  • 17.18. Phibro Animal Health Corporation
  • 17.19. Recombinetics, Inc.
  • 17.20. Thermo Fisher Scientific Inc.
  • 17.21. Trans Ova Genetics, LC
  • 17.22. Vetoquinol S.A.
  • 17.23. Virbac S.A.
  • 17.24. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL BIOTECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 263. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 267. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 268. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 270. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 271. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 272. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 276. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 305. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 306. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 308. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 309. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 310. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 312. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 313. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 314. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 316. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 317. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 318. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 319. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 320. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 322. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 323. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 324. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 325. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 326. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 327. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUEN